Amphastar Pharmaceuticals on Tuesday revealed that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Glucagon for Injection Emergency Kit, 1 mg.
Glucagon is used for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Amphastar said its synthetic peptide product was determined by the FDA to be therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“This approval is yet another milestone for the Company and marks the first-ever FDA approval of a generic version of rDNA Glucagon,” commented Dr Jack Zhang, Amphastar’s CEO and President.
According to IQVIA data, US sales for Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar were approximately $144 million, with the overall US sales of brand products containing glucagon for injection, 1 mg, being roughly $306 million for the 12 months ended September 30.
Amphastar plans to launch its kit within two months.
The company’s stock price has risen by over 26% premarket, trading at $23.98 following Monday’s close ta $19.02.
